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Abstract
We determined whether the implantation of human pan-
creatic cancer cells into the pancreas of nude mice can
be used to select variants with increasing metastatic
potential. COLO 357 line fast-growing cells were in-
jected into the spleen or pancreas of nude mice. Hep-
atic metastases were harvested, and tumor cells were
reinjected into the spleen or pancreas. This cycle was
(repeated several times to yield cell lines L3.6sl spleen
) ( )to liver and L3.6pl pancreas to liver . The variant cells
produced significantly higher incidence and number of
lymph node and liver metastases than the parental
cells. Their increased metastatic potential was associ-
( )ated with increased expression mRNA and protein of
the proangiogenic molecules basic fibroblast growth
factor, vascular endothelial growth factor, and inter-
leukin-8. The metastatic cells also exhibited increased
motility and invasiveness, which were associated with
( )increased expression of collagenase type IV MMP-9
and decreased expression of E-cadherin. Collectively,
the data show that the orthotopic implantation of hu-
man pancreatic cancer cells in nude mice is a relevant
model with which to study the biology of pancreatic
cancer metastasis and to select variant cell lines with
enhanced metastatic potential.
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Introduction
Cancer of the exocrine pancreas is a major unsolved health
problem with approximately 27,000 deaths per year in the
United States and 50,000 deaths per year in Western Eu-
[ ]rope 1,2 . It is characterized by extensive local invasion as
well as early lymphatic and hematogenous metastasis. Due
to the inability to detect pancreatic cancer at an early stage,
its aggressiveness, and the lack of effective systemic thera-
pies, only 1% to 4% of all patients with adenocarcinoma of
[ ]the pancreas will be alive 5 years after diagnosis 3–6 .
Because most deaths from pancreatic cancer are caused by
metastasis, improvements in treatment require a better un-
derstanding of the biology of this process.
The process of metastasis consists of sequential and
selective steps that include proliferation, induction of angio-
genesis, detachment, motility, invasion into the circulation,
aggregation and survival in the circulation, cell arrest in
distant capillary beds and extravasation into the organ
parenchyma, response to local growth factors, induction of
[ ]angiogenesis, and proliferation 7 . The outcome of metasta-
sis is determined by multiple interactions between metastatic
[ ]tumor cells and host factors 7,8 . To produce clinically
relevant metastases, tumor cells must complete all steps in
[ ]the metastatic cascade 7 . Thus, the failure to produce a
metastasis can be due to different single or multiple defi-
[ ]ciencies 9 .
The process of metastasis is highly selective and its
outcome depends on the interaction of metastatic cells that
preexist within a heterogeneous primary neoplasm and a
[ ]variety of host factors 7,8 . Critical to our studies has been
the development of relevant in vivo models for cancer
[ ]metastasis 10,11 , which have produced conclusive evi-
dence that the outcome of metastasis is regulated by the
interaction of unique tumor cells with homeostatic mecha-
[ ]nisms 7,8 . Indeed, studies from our laboratory and others
have shown that malignant human tumors implanted into
orthotopic organs are highly vascularized, grow progres-
sively, and produce distant metastasis, whereas the implan-
tation of the same tumors at an ectopic organ does not lead
[to extensive angiogenesis or production of metastasis 12–
] (20 . Similarly, the isolation of multiple variants from biologi-
)cally heterogeneous neoplasms that differ in metastatic
properties has greatly advanced our understanding of the
genetic and epigenetic determinants of cancer metastasis
[ ]7–9 .
Two general methods have been used to select metastatic
variants in vivo. In the first, tumor cells are implanted into
orthotopic organs, and spontaneous metastases from dis-
tant organs are isolated and reinjected into orthotopic or-
( )Abbreviations: matrix metalloproteinase-2 MMP-2 ; bFGF, basic fibroblast growth
factor; DAB, diaminobenzidine; FBS, fetal bovine serum; FG, fast growing line;
HBSS, Hank’s balanced salt solution; HUVEC, human umbilical vein endothelial
cells; IHC, immunohistochemistry; ISH, in situ hybridization; MMP, matrix metallo-
proteinase; OD, optical density; PCNA, proliferating cell nuclear antigen; VEGF/
VPF, vascular endothelial growth factor/vascular permeabilit factory
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gans. In the second method, tumor cells are introduced into
the circulation to produce lesions in distant organs, or ex-
perimental metastases. Spontaneous metastases then oc-
cur subsequent to completion of all steps of the metastatic
process, whereas experimental metastases reflect the abil-
ity of tumor cells to survive in the circulation, arrest in a
distant capillary bed, and grow in a distant organ paren-
[ ]chyma 7–11 .
Unfortunately, such models do not exist for pancreatic
cancer. The purpose of the present study was, therefore, to
develop an orthotopic model for metastasis of human pan-
( )creatic cancer, to select in vivo variant lines with increas-
ing metastatic capacity, and to begin detailed characteriza-
tion of their properties. To do so, we used the COLO 375
human pancreatic cancer cell line originally established by
[ ]Morgan et al. 21 from a celiac axis lymph node that had
been partially replaced by neoplastic foci of well-differenti-
ated, mucin-containing pancreatic ducts. Vezeridis et al.
( )subsequently injected the fast-growing FG variant line of
the COLO 375 cells into the spleen of nude mice. The in
vivo isolated cells designated as L3.3 produced liver lesions
[ ]at a higher incidence than the original COLO 375 cells 22 .
In the present study, we show that orthotopic implanta-
tion of heterogeneous human pancreatic adenocarcinoma
into nude mice results in rapid growth and production of
lymph node and liver metastases. Cells isolated from the
metastases were more metastatic because they expressed
several genes that correlate with production of metastasis.
Materials and Methods
Animals
( )Male athymic nude mice BALB/c background were
purchased from the Animal Production Area of the National
Cancer Institute-Frederick Cancer Research and Develop-
( )ment Center Frederick, MD . The mice were housed and
maintained in laminar flow cabinets under specific
pathogen-free conditions in facilities approved by the Ameri-
can Association for Accreditation of Laboratory Animal Care
and in accordance with current regulations and standards of
the US Department of Agriculture, US Department of Health
and Human Services, and the National Institutes of Health.
The mice were used in accordance with institutional guide-
lines when they were 8 to 12 weeks old.
Pancreatic Cancer Cell Lines and Culture Conditions
[ ]The FG and L3.3 21,22 human pancreatic cancer cell
lines were maintained as monolayer cultures in Dulbecco’s
( )minimal essential medium DMEM , supplemented with 10%
( )fetal bovine serum FBS , sodium pyruvate, nonessential
(amino acids, L-glutamine, and a 2-fold vitamin solution Life
)Technologies, Rockville, MD . The cultures were incubated
at 378C in a mixture of 5% carbon dioxide and 95% oxygen.
The cultures were tested and found to be free of My-
coplasma and the following pathogenic murine viruses: re-
ovirus type 3, pneumonia virus, K virus, Theiler’s encephali-
tis virus, Sendai virus, minute virus, mouse adenovirus,
mouse hepatitis virus, lymphocytic choriomeningitis virus,
(ectromelia virus, and lactate dehydrogenase virus assayed
)by M. A. Bioproducts, Walkersville, MD . The cultures were
maintained for no longer than 12 weeks after recovery from
frozen stocks.
Tumor Cell Injection Techniques
For in vivo injection, cells were harvested from culture
flasks by a 2 to 3 minutes treatment with trypsin and were
transferred to serum-free Hanks’ balanced salt solution
( )HBSS . Only single-cell suspensions of greater than 90%
( )viability trypan blue exclusion were used for injection.
Orthotopic injection Male nude mice were anesthetized with
methoxyflurane. A small left abdominal flank incision was
( 6made and the spleen exteriorized. Tumor cells 1=10 /40
)mL HBSS were injected subcapsularly in a region of the
pancreas just beneath the spleen. We used a 30-gauge
needle, a 1-mL disposable syringe, and a calibrated, push-
button-controlled dispensing device to inject the tumor cell
( )suspension Hamilton Syringe Co, Reno, NV . A successful
subcapsular intrapancreatic injection of tumor cells was
identified by the appearance of a fluid bleb without intraperi-
toneal leakage. To prevent such leakage, a cotton swab
was held for 1 minute over the site of injection. One layer of
(the abdominal wound was closed with wound clips Auto-
)clip; Clay Adams, Parsippany, NJ . The animals tolerated
the surgical procedure well, and no anesthesia-related
deaths occurred.
Intrasplenic inoculation Tumor cells were injected into the
[ ]spleen by methods previously described in detail 11,12 .
Briefly, mice were anesthetized with methoxyflurane, a small
left abdominal flank incision was created, and the spleen
( 6 )was exteriorized. Tumor cells 1=10 /40 mL HBSS were
injected into the spleen with a 30-gauge needle. The spleen
was returned to the abdomen, and the wound was closed in
one layer with wound clips.
( 6Intravenous injection Tumor cells 1=10 cells /200 ml
)HBSS were injected into the lateral tail vein of unanes-
thetized nude mice with a 27-gauge needle.
Necropsy Procedure and Histopathological Studies 1
Mice were euthanized by methoxyflurane. The presence
of tumor lesions in the pancreas, spleen, lymph nodes, liver,
lung, and other peritoneal organs was confirmed with a
dissecting microscope. The number of visible liver and lung
metastases, as well as enlarged regional lymph nodes, was
determined with the aid of a dissecting microscope. Tumor
lesions were harvested. Some were snap-frozen in liquid
nitrogen for mRNA extraction; some were fixed in 10%
1This work was supported in part by Cancer Center Support Core Grant CA16672
and grant R35-CA42107 from the National Cancer Institute, National Institutes of
Health, CaP CURE, and the Lise-Meitner-Stipendium, German Research Associa-
tion, Nordrhein-Westfalen, Germany.
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buffered formalin and embedded in paraffin, and some were
( )embedded in OCT compound Miles, Inc, Elkhart, IN ,
snap-frozen in liquid nitrogen, and stored at y708C.
In Vivo Selection of Metastatic Variants from the L3.3 Hu-
man Pancreatic Cancer Cell Line
L3.3 cells were injected into the pancreas or spleen of
( )nude mice. Experimental spleen injection or spontaneous
( )pancreas injection liver metastases were harvested and
[ ]treated with DNase and collagenase 12,13 . Cells were
established in culture. Primary cultures were passaged in
vitro 2 or 3 times, and then cells were harvested by
trypsinization and injected into the spleen or pancreas of
another set of nude mice. The selection cycle was repeated
(3 times to yield lines designated as L3.6sl spleen to liver
) ( )selection or L3.6pl pancreas to liver selection .
Immunohistochemistry
Paraffin-embedded tissues were sectioned at 4 to 6 mm
thickness, mounted on positively charged Superfrost slides
( )Fisher Scientific Co, Houston, TX , and allowed to dry
overnight at room temperature. Sections were deparaf-
finized in xylene followed by a graded series of ethanol
( )100%, 95%, 80% , and rehydrated in phosphate-buffered
)solution, pH 7.5 . Paraffin-embedded tissues were used for
localization of vascular endothelial growth factor/vascular
( )permeability factor VEGF/VPF , basic fibroblast growth fac-
( ) ( )tor bFGF , matrix metalloproteinase-9 MMP-9 , and prolif-
( )erating cell nuclear antigen PCNA proteins. Sections ana-
lyzed for PCNA and MMP-9 were microwaved 5 minutes for
[ ]antigen retrieval 23 . All other paraffin-embedded tissues
(were treated for 5 minutes with pepsin Biomeda, Foster
)City, CA at 378C and then washed 3 times with PBS. To
[ ]identify CD-31/PECAM-1 24 , frozen tissues were sec-
( )tioned 8–10 mm , mounted on positively charged Plus
( )slides Fisher Scientific , and air-dried 30 minutes. Frozen
( )tissues were fixed in cold acetone 5 min , acetone/
( ) ( )chloroform 1:1 5 min , and acetone 5 min and washed 3
times with PBS.
After the specific pretreatment procedures, all samples
were incubated with a 3% H O in methanol solution for 122 2
minutes at room temperature to block endogenous peroxi-
dases. Sections were then washed 3 times with PBS and
then incubated for 20 minutes at room temperature in a
protein-blocking solution consisting of PBS supplemented
with 1% normal goat serum and 5% normal horse serum.
The primary antibodies were diluted in protein blocking
solution to the desired concentration and applied to the
sections overnight at 48C. The sections were then rinsed in
PBS and incubated for 10 minutes in protein-blocking solu-
tion before the addition of peroxidase-conjugated secondary
antibody. After incubation in secondary antibody for 1 hour
at room temperature, the samples were washed and incu-
(bated with stable diaminobenzidine DAB, Research Genet-
)ics, Huntsville, AL . Staining was monitored under a bright-
field microscope, and the reaction was stopped by washing
with distilled water. Sections were counterstained with Gill’s
( )3 hematoxylin Sigma Chemical Co, St. Louis, MO and
( )mounted with Universal Mount Research Genetics . The
concentration of primary and secondary antibodies was
determined by using separate specimens. Control speci-
mens exposed to secondary antibody alone showed no
specific staining.
Quantification of Microvessel Density and Immunohisto-
chemistry
( )For the quantification of microvessel density MVD ,
frozen sections of the different pancreatic tumors were fixed
[ ]and stained with antibodies against CD31/PECAM-1 24 .
For each tumor, four fields of 1 mm2 each were captured at
[ ]40= magnification with highest intensity 25–27 by using a
(Sony 3-chip camera Sony Corporation of America, Mont-
) (vale, NJ mounted on a Zeiss universal microscope Carl
)Zeiss, Thornwood, NY and Optimas Image Analysis soft-
( )ware Bioscan, Edmond, WA , installed in a Compaq com-
puter with Pentium chip, a frame grabber, an optical disk
storage system, and a Sony color printer.
For quantification of the staining intensity, the optical
( )density OD at 200= magnification of 100 VEGF/VPF,
bFGF, and MMP-9 positive cells from each tumor tissue
was measured by using the Optimas Image Analysis soft
( )ware Bioscan . The samples were not counterstained, so
the OD was due solely to the product of the immunohisto-
( ) [ ]chemical IHC reaction 27 . To minimize changes in back-
ground and color intensities that may be encountered with
fluctuation in illumination due to filament life or optical align-
ment, all images to be used for analysis were digitized and
stored for further analysis. The intensity of staining with the
different antibodies was standardized to that of the inte-
grated OD and determined by comparison with the inte-
[ ]grated OD of the FG tumor, which was set at 100 27 .
For quantification of PCNA expression, the number of
PCNAq cells was counted in four fields of 0.161-mm2 each
at 100= magnification at the areas of most intense PCNA
expression.
Antibodies and Oligonucleotide Probes
All antibodies were purchased as listed: rabbit anti-bFGF
( ) (Sigma , rabbit anti-VEGF/VPF Santa Cruz, Santa Cruz,
) (CA , monoclonal mouse anti-MMP-9 AB3 Oncogene Re-
)search, Uniondale, NY , rat anti-mouse CD31/PECAM-1
(and peroxidase-conjugated rat anti-mouse IgG1 Pharmin-
) (gen, San Diego, CA , mouse anti-PCNA clone PC 10 DAKO
)A / S, Copenhagen, Denmark , peroxidase-conjugated
( X) ( X)F ab goat anti-rabbit IgG F ab and peroxidase-con-2 2
[ ] (jugated goat anti-rat IgG HqL Jackson Research Labora-
)tories, West Grove, CA , peroxidase-conjugated rat
(anti-mouse IgG2a Serotec, Harlan Bioproducts for Science,
) ( X)Inc., Indianapolis, IN , and peroxidase-conjugated F ab 2
( )anti-mouse IgG1 Oncogene .
Specific antisense oligonucleotide DNA probes were de-
signed complementary to the mRNA transcripts of metasta-
(sis and angiogenesis-related genes MMP-2, MMP-9,
[ ])E-cadherin, VEGF, bFGF, interleukin-8 IL-8 based on
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published reports of the cDNA sequence: VEGF/VPF
( X X X X X X X X )TGG TGA TGT TGG -ACT CCT CAG TGG GCU , 57.7%
( ) [ ] ( X Xguanosine-cytosine CG content 28 ; bFGF CGG GAA-
X X X X X) [ ]GGC GCC GCT GCC GCC , 85.7% GC content 27 ; IL-8
( X X X X X X ) [ ]CTC CAC AAC CCT CTG CAC CC , 65% GC content 29 ;
( X X X X X X X X )MMP-2 TGG GCT ACG GCG CGG CGG CGT GGC ,
[ ] ( X X X X88.9% GC content 30 ; MMP-9 CCG GTC CAC CTC -
X X X X ) [ ]GCT GGC GCT CCG GU , 80.0% GC content 31 ;
( ) ( X X X X X XE-cadherin mixture TGG AGC GGG CTG GAG TCT -
X X) ( X X X XGAA CTG , 62.5% CG content and GAC GCC GGC GGC -
X X X X) [ ]CCC TTC ACA GTC , 75% CG content 32 . The specificity
of the oligonucleotide sequence was initially determined by
Gene Bank European Molecular Biology Library database
search with the use of Genetics Computer Group sequence
( )analysis program GCG, Madison, WI based on the FastA
[ ]algorithm 33 . These sequences showed 100% homology
with the target gene and minimal homology with nonspecific
mammalian gene sequences.
In Situ Hybridization
( )In situ hybridization ISH was carried out according to
(the microprobe manual staining system Fisher Scientific
) [ ] ( )Co, Pittsburgh, PA 34,35 . Tissue sections 5 mm of
formalin-fixed, paraffin-embedded specimens were mounted
( )on Silane-coated ProbeOn slides Fisher Scientific . The
slides were placed in the microprobe slide holder, dewaxed,
(and dehydrated with Autodewaxer and Autoalcohol Re-
)search Genetics , followed by an enzymatic digestion with
[ ]pepsin 36 . Hybridization of the biotinylated probe was
carried out sequentially for 3 minutes at 1008C, 4 minutes at
room temperature, and 45 minutes at 458C. The samples
were then washed 3 times with 2= standard saline citrate
( )SSC for 2 minutes at 458C. The samples were incubated
for 30 minutes in alkaline phosphatase–labeled avidin
( )DAKO, Carpineria, CA at 458C, briefly rinsed in Tris-
( [ ]buffered saline 50 mmol/L Tris–HCl pH 7.6 , 150 mmol/L
)NaCl , rinsed for 1 minute in alkaline phosphatase enhancer
( )Biomeda Corp, Foster City, CA , and finally incubated for
(30 minutes with chromogen substrate FastRed Research
)Genetics at 458C. Slides were washed several times with
distilled water, counterstained with Gill’s 3 hematoxylin
( ) (Sigma , and mounted with Universal Mount Research Ge-
)netics . A positive reaction in this assay stained red. Control
for endogenous alkaline phosphatase included treatment of
the samples in the absence of the biotinylated probe and
use of chromogen in the absence of any oligonucleotide
probes. To check the specificity of the hybridization signal,
)the following controls were used: 1 RNase pretreatment of
) )tissue sections; 2 a biotin-labeled sense probe; and 3
[ ]competition assay with unlabeled antisense probe 37 . A
markedly decreased or absent signal was obtained after all
of these treatments.
Stained sections were examined under a Zeiss photo-
( )microscope Zeiss equipped with a 3-chip-charged coupled
( )device color camera model DXC-960 MD, Sony . The im-
ages were analyzed by using the Optimas Image Analysis
( )software version 5.2, Bothell, WA . The samples were not
counterstained, so the OD was due solely to the product of
the ISH reaction. For each section, we determined the OD
in several 2=2 mm zones located at the center and periph-
ery of the tumor. Three to five different fields in each 2=2
mm zone were quantified to derive an average value. The
intensity of staining was standardized to that of the inte-
( )grated OD of poly d T0 and determined by comparison20
with the integrated OD of nonpathological pancreatic epithe-
lial cells, which was set at 100.
In Vitro Growth Kinetics
Pancreatic cancer cells were harvested from 75% conflu-
ent monolayer cultures by a brief trypsinization with 0.1%
trypsin and 0.1% EDTA. The cells were washed in cold
HBSS, plated at a density of 1500 cells per 38-mm2 well,
and then given supplemented DMEM containing 10% FBS.
Cell growth was monitored after 8 hours and 1, 2, 3, and 4
[ ]days by using the MTT assay as described previously 38 .
In vitro doubling times were calculated from the log phase
[ ]growth curve 39 .
In Vitro Migration Assay
A modified Boyden chamber assay was used to examine
the in vitro motility of the different pancreatic cancer cells.
( )Polycarbonate filters pore size, 8 mm; diameter, 13 mm
were glued to inserts, which were placed in the wells of
24-well tissue culture plates. The lower part of the chamber
( )was filled with fibronectin 100 ng/mL as a chemo-
( 4)attractant. Cells 2=10 were suspended in 100-ml HBSS
and placed in the upper part of the chamber. After 6 hours
incubation at 378C, the filters were carefully removed from
the inserts, stained with hematoxylins losin for 10 minutes,
and mounted on microscopic slides. The number of stained
(cells was counted in 10 microscopic fields each 0.161
2)mm at 100= magnification. Migratory activity was quanti-
fied by the average number of cells per microscopic field.
Endothelial Cell Proliferation Assay
( )Primary human umbilical vein endothelial cells HUVEC
were cultured in complete DMEM containing 15% FBS and
10 ng/mL bFGF. Cell culture flasks were coated with 4
mg/mL gelatin. Cells were plated in 96-well plates at a
density of 3=103 cells per well. After 24 hours, the super-
natant in each well was removed, and 200 ml of conditioned
medium of the different pancreatic cancer cells was added
(in various concentrations 10% and 50% conditioned
)medium . Conditioned medium was prepared by culturing
5=105 pancreatic cancer cells in a 6 well plate in supple-
mented DMEM containing 10% FBS for 5 days. After 4 days
of incubation, the growth of HUVECs in various concen-
trated conditioned media of the different pancreatic cancer
cells was monitored by MTT assay and compared to the
growth of HUVECs treated with supplemented DMEM con-
taining 15% FBS and 10 ng/mL bFGF only.
Statistical Analysis
The unpaired Student t test was used to compare the in
vitro and in vivo results. Survival analysis was computed by
the Kaplan–Meier method and compared by the log-rank
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Figure 1. In vivo selection of metastatic human pancreatic cancer cells.
( )L3.3 cells derived from the FG line were injected into the spleen or the
( )pancreas of nude mice. Experimental liver metastases spleen injection
( )or spontaneous liver metastases pancreas injection were harvested,
( )established in culture, and designated L3.4sl spleen– liver and L3.4pl
( )pancreas– liver . The cultures were harvested and injected into the
spleen or pancreas of another set of nude mice. The cycles were
repeated twice more to yield lines L3.6sl and L3.6pl.
[ ]test 40 . The Mann–Whitney test was used to compare the
level of gene expression among the different cell lines
( )univariate analyses . Significance was defined as a
[ ]two-sided P- .05 40 .
Results
Selection of Highly Metastatic Variant Lines
In the first set of experiments, we injected cells from the
FG line derived from COLO357 human pancreatic adeno-
[ ]carcinoma cell line 21,22 into the spleen or pancreas of
nude mice. Intrasplenic injection allows cells to reach the
[ ]liver parenchyma within minutes after injection 13,14 . Liver
colonization can occur rapidly and without necessity to
overcome the barrier of the primary site microenvironment.
The liver lesions thus formed are termed experimental
metastases. In contrast, to produce liver lesions, human
pancreatic cancer cells implanted into the pancreas must
Figure 2. Percent cumulative survival. The pancreases of nude mice
were injected with 1=10 6 viable FG, L3.6sl, or L3.6pl cells. Moribund
mice were killed and necropsied. Survival analysis was computed by the
Kaplan–Meier method, and the unpaired Student t test was used to
compare the results among the three different cell lines. FG versus
L3.6sl, P- .002; FG versus L3.6pl, P- .0001; L3.6sl versus L3.6pl,
P- 0.02.
complete all the steps of the process. The lesions then are
designated as spontaneous metastases. Experimental or
spontaneous liver metastases were harvested, established
in tissue culture, and designated as L3.4sl and L3.4pl,
respectively. Cells harvested from these cultures were in-
jected into the spleen or pancreas of another set of nude
mice. Liver lesions were again isolated, and cells were
established in culture. After three such selection cycles,
(lines L3.6sl and L3.6pl were established in culture Figure
)1 . Cytogenetic analysis confirmed the human origin of the
cells.
To determine whether the isolated variants had in-
creased metastatic potential, cells from the original FG line
and from the L3.6sl, and L3.6pl lines were injected into the
( )spleen and/or the pancreas of nude mice ns20 . The
mice were killed when moribund or by day 105 after injec-
tion. Tumorigenicity, production of metastases, and survival
( )were determined Table 1 . In the first assay for experimen-
tal metastasis, we injected the cells into the spleen. In-
Table 1. Tumorigenicity and Production of Metastasis by Human Pancreatic Cancer Cells Subsequent to Implantation in Athymic Nude Mice.
)Site of Implantation Cell Line Median Survival Tumorigenicity Liver Metastasis Lymph Node
‡†( )days Metastasis( )Incidence Median range
( )Spleen FG 92 5/20 4/20 0 0–2 2/10
5 §( )L3.6sl 71 19/20 10/19 3 0–10 7/19
5 ( )L3.6pl 34 20/20 13/20 10 0–75 3/20
( )Pancreas FG 78 20/20 1/20 0 0–1 3/20
5( )L3.6sl 56 20/20 5/20 0 0–3 12/20
§( )L3.6pl 36 20/20 10/20 1 0–15 9/20
)Nude mice were injected into the spleen, pancreas or vein with 1= 106 viable cells. The mice were killed when moribund and necropsied. The
presence of tumor lesions in the spleen, pancreas, liver, lymph nodes, or lungs was determined with the aid of a dissecting microscope.
†Number of tumor-positive mice per number of injected mice.
‡Number of mice with macroscopically enlarged regional lymph node per number of injected mice.
§P- .01 versus FG.
5P- .001 versus FG.
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trasplenic injection of FG cells produced spleen tumors in 5
of 20 animals, experimental liver metastases in 4 of 20
mice, and a median survival time of 92 days. Injection of
L3.6sl cells produced spleen tumors in 19 of 20 mice,
Figure 3. Representative IHC staining of FG, L3.6sl, and L3.6pl human pancreatic cells growing in the pancreas of nude
( )mice. Tissue sections were stained for expression of PCNA to show cell division , MMP-9, IL-8, bFGF, VEGF/VPF, and
( )CD31 to show endothelial cells .
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( )experimental liver metastases in 10 of 19 mice P- .01 ,
and a median survival time of 71 days. For L3.6pl cells, 20
of 20 mice had spleen tumors and 13 of 20 had liver
( )metastases P- .01 ; the median survival time was 34 days
( )P- .01 . The highest median number of liver metastases
( )was 10 3–75 , found after intrasplenic injection of L3.6pl
cells, suggesting that these cells have a higher capacity to
colonize the liver.
In the second assay for spontaneous metastasis, we
injected the cells into the pancreas. All three lines were
( )100% tumorigenic after intrapancreatic injection Table 1 .
Liver metastases were produced in 1 of 20, 5 of 20, and 10
of 20 mice after injection of FG, L3.6sl, and L3.6pl cells,
respectively. The median survival time was 84, 56, or 36
days after the intrapancreatic injection of FG, L3.6sl, and
( )L3.6pl cells, respectively Figure 2 . These data show that
selection of cells for experimental metastasis also increased
their ability to form spontaneous metastasis. The selection
of cells for spontaneous metastasis, however, yielded cells
with the highest metastatic potential.
( ) 6The intravenous IV injection of 1=10 FG cells pro-
duced a median of 75 experimental lung metastasis per
( )mouse range, 18–142 , whereas the intravenous injection
of L3.6sl cells produced a median number of 3 lung lesions.
The IV injection did not yield a significant number of liver
metastases.
Cell Growth in Vitro and in Vivo
The in vitro doubling time of FG, L3.6sl and L3.6pl was
25, 20, and 16 hours, respectively. The average number of
( )PCNAq cells per microscopic field in the pancreatic tu-
mors agreed with the in vitro results. The average number
of PCNAq cells per microscopic field was 178"42, 289"
48, and 399"33 in 72- to 84-day-old pancreatic tumors of
FG, 53- to 59-day-old pancreatic tumors of L3.6sl, and 35-
to 37-day-old pancreatic tumors produced by L3.6pl cells
( )Figure 3; Table 2 .
Cell Motility
To determine whether the increased metastatic potential
was associated with increased motility, we used a modified
( )Boyden chamber assay with fibrinogen 100 ng/mL as a
chemoattractant. The motility of L3.6sl and L3.6pl cells
differed significantly from that of the FG cells. Specifically,
the number of FG, L36sl, and L3.6pl cells per 10 micro-
scopic fields was 3"1, 38"5, and 44"7 cells, respec-
( )tively P- .001 .
Relative Expression of MMP-2/MMP-9 and E-cadherin
Detachment of malignant cells from the primary tumor
and penetration of host stroma including basement mem-
( )branes and extracellular matrix ECM is an essential part of
[ ]the metastatic process 7 . The degradation of the ECM
components surrounding malignant tumors is primarily me-
[ ]diated by MMPs or type IV collagenases 41–46 . To deter-
mine whether the metastatic potential of the variant cells
correlated with their production of MMPs, we examined the
expression of MMPs by ISH.
Pancreatic tumors derived from L3.6pl and L3.6sl cells
had significantly higher MMP-9 and MMP-2 mRNA levels
( )than tumors derived from FG Figure 4, Table 3 . The
MMP-9 mRNA expression level was significantly higher in
(pancreatic tumors derived from L3.6pl cells spontaneous
) ( )metastasis than in L3.6sl cells experimental metastasis .
The expression of E-cadherin, a transmembrane glyco-
protein that is directly related to cell-to-cell cohesion, was
high in tumors derived from FG and low in tumors derived
from L3.6sl and L3.6pl cells. IHC staining of pancreatic
tumors with anti-MMP-9 antibody revealed a significant in-
crease in the expression of MMP-9 protein in tumors de-
(rived from metastatic L3.6sl and L3.6pl cells Figure 3,
)Table 2 .
Gelatin zymography of tumor lysates revealed 5-fold and
3.5-fold increases in activity of the 92-kDa MMP-9 in pan-
( )creatic tumors or culture supernatants derived from L3.6sl
and L3.6pl cells, respectively, as compared with FG cells.
MMP-2 activity was indistinguishable among the 3 different
tumors. Additionally, a 3-fold increase of MMP-9 activity
was determined in lysates of pancreatic tumors from L3.6pl
( )versus L3.6sl cells Figure 5 .
Expression of VEGF, bFGF, IL-8, and Quantification of
Microvessel Density
In situ hybridization of tissue sections demonstrated a
significant difference in VEGF/VPF, bFGF, and IL-8 mRNA
Table 2. Immunohistochemical Analysis of Pancreatic Cancers Produced by Orthotopic Implantation in Athymic Nude Mice.
) † ‡ § § § §Cell Line PCNA CD-31 VEGF/VPF bFGF IL-8 MMP-9
( ) ( ) ( ) ( ) ( ) ( )FG 180 152–228 7 6–13 100 97–108 100 92–103 100 97–105 100 98–107
( ) ( ) ( ) ( ) ( ) ( )L3.6sl 262 244–350 35 33–57 133 130–139 136 131–147 141 137–145 123 118–124
( ) ( ) ( ) ( ) ( ) ( )L3.6pl 374 366–391 73 59–112 178 168–185 176 169–182 157 155–165 145 133–150
)Tumor cells were injected into the pancreas of athymic nude mice. Tumors were harvested and processed for IHC as described in Materials and
Methods.
† ( ) 2Median range number of PCNAq cells was determined by counting positive cells in four fields of 0.161 mm each at 100= magnification. FG v
L3.6sl, P- .004; FG v L3.6pl, P- .002; L3.6sl v L3.6pl, P- 0.002.
‡ ( ) 2Median range number of CD31-positive cells was determined by counting positive cells in four fields of 1.0 mm each at 40= magnification at the
area of most intense CD31 expression. FG v L3.6sl, P- .01; FG v L3.6pl, P- .006; L3.6sl v L3.6pl, P- .01.
§ ( )Median range OD of VEGF/VPF, bFGF, and MMP-9 was determined by measurement of 100 cells per tumor at 200= magnification with the
Optimas Image Analysis software. The integrated OD was compared with the integrated OD in the FG tumors, which was set at 100. VEGF/VPF: FG v
L3.6sl, P- .05; FG v L3.6pl, P- .01; L3.6sl v L3.6pl, P- 0.05. bFGF: FG v L3.6sl, P- .05; FG v L3.6pl, P- .01; L3.6sl v L3.6pl, P- .05. MMP-9: FG
v L3.6al, P- .05; FG v L3.6pl, P- .02; L3.6sl v L3.6pl, P- .04.
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Figure 4. Representative ISH of FG, L3.6sl, and L3.6pl human pancreatic cells growing in the pancreas of nude mice.
( )Metastatic cells L3.6sl, L3.6pl concurrently expressed high levels of MMP-2, MMP-9, bFGF, VEGF/VPF, IL-8, and low
levels of E-cadherin. The low metastatic cells expressed high levels of E-cadherin.
expression level among pancreatic tumors derived from FG,
( )L3.6sl, and L3.6pl cells see Figure 4 . IL-8 mRNA expres-
sion level was significantly higher in pancreatic tumors de-
( )rived from L3.6pl than in L3.6sl or FG cells see Figure 4 .
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Table 3. In Situ Hybridization Analysis for Relative Expression of Metastasis-Regulating Genes by Human Prostate Cancer Cell Lines Growing in the
Pancreas of Nude Mice.
( )Cell Line Median Expression Index Range MMP/E-Cadherin Ratio
VEGF/VPF bFGF IL-8 MMP-2 MMP-9 E-cadherin
( ) ( ) ( ) ( ) ( ) ( ) ( )FG 146 127–147 166 155–172 84 75–940 119 96–142 92 83–100 73 65–80 1.5 1.4–1.5
( ) ( ) ( ) ( ) ( ) ( ) ( )L3.6sl 295 163–353 263 223–285 208 210–215 201 180–225 186 167–195 55 46–56 3.7 3.3–4.0
( ) ( ) ( ) ( ) ( ) ( ) ( )L3.6pl 280 233–315 240 224–252 198 149–210 200 171–248 146 152–150 48 41–55 3.8 3.3–3.9
P value
FG v L3.6sl .001 .0006 .001 .0006 .002 .006 .0006
FG v L3.6pl .001 .0006 .001 .0006 .001 .006 .0006
L3.6sl v L3.6pl NS NS .02 NS .001 NS NS
Note: Tumor cells were injected into the pancreas of athymic nude mice. Tumors were harvested and processed for in situ hybridization analysis as
described in Materials and Methods. Relative expression of specific mRNA was determined by examining at least 7 different fields/specimen. The
expression of each gene in normal epithelium of mouse pancreas was set at the value 100.
Similar results were obtained in vitro by Northern blot analy-
( )sis of cultured cells data not shown .
IHC staining with specific antibodies demonstrated in-
creased protein expression of VEGF/VPF, bFGF, or IL-8 in
( ) (L3.6sl and L3.6pl tumors see Figure 3, Table 2 FG v
)L3.6sl /L3.6pl, P- .01, L3.6sl v L3.6pl, P- .03 . These in
vivo results are supported by Western blot analysis of tissue
culture lysates for bFGF as well as ELISA assay of culture
( )supernatants for IL-8 and VEGF/VPF data not shown .
To determine whether the proangiogenic molecules pro-
duced by the pancreatic tumor cells were biologically active,
we incubated HUVEC with culture supernatants of the three
cell lines and determined HUVEC proliferation by the MTT
[ ]assay 38,39 . Conditioned media of FG, L3.6sl, and L3.6pl
( )cells stimulated proliferation of HUVECs P- .02 . To fur-
ther investigate angiogenesis in the orthotopic tumors, we
quantified MVD after staining frozen sections of tumors with
CD31/PECAM-1. In pancreatic tumors derived from FG,
L3.6sl, and L3.6pl, the average number of CD31/PECAM-1
( 2 )positive vessels per 1-mm field at 40= magnification
( )was 3"1, 44"11, and 89"25, respectively P- .001 .
Figure 5. Gelatin zymography. Lysates from FG L3.6sl and L3.6pl
( )pancreatic tumors were prepared. Protein 1 mg was loaded on a 7.5%
polyacrylamide slab gel- impregnated with 1 mg/mL gelatin under
nonreducing conditions.
Discussion
Metastasis is a highly selective process that favors the
survival and growth of unique subpopulations of metastatic
cells that preexist within heterogeneous malignant neo-
[ ]plasms 47,48 . The isolation of clonal populations of cells
that differ in their metastatic capacity has supported the
[ ]hypothesis of metastatic heterogeneity 7–10,48 . Depend-
ing on the neoplasm, the selection process is gradual,
[ ]requiring several cycles of in vivo selection 12,16,19 . This
cyclic procedure was originally used to isolate the B16-F10
metastatic cell line from the wild-type B16 murine melanoma
[ ]cell line 47 and, subsequently, human renal cell carcinoma
[ ] [ ]13 , colon carcinoma 11,12 , transitional cell carcinoma
[ ] [ ]15,16 , and prostate carcinoma 18,19 . We implanted pan-
(creatic cancer cells into the spleen experimental liver
) ( )metastasis or pancreas spontaneous liver metastasis and
harvested metastatic lesions. The recovered cells were ex-
panded in culture to repeat the process. After several cy-
cles, the behavior of the cells was compared with that of the
parental cells. The metastatic potential of the pancreatic
cancer cells in nude mice was determined by two assays.
The first involved the implantation of the cells into the
pancreas and a count of spontaneous lymph nodes and
liver metastasis. The second measured to ability of the
pancreatic cancer cells to grow in the liver parenchyma
(subsequent to intrasplenic implantation experimental
)metastasis . In general, there was good agreement in the
results of the two assays.
Earlier data from our laboratory established that the im-
plantation site of metastatic human tumor cells determines
whether they will produce distant metastasis. Specifically,
the growth of tumors in orthotopic organs facilitates produc-
tion of metastasis, whereas growth in ectopic organs does
[ ]not 7–10 . Indeed, human pancreatic cancer cells im-
( ) ( )planted into the pancreas orthotopic or subcutis ectopic
of severe combined immunodeficient mice produced tumors
[ ]that differed in growth rate and status of differentiation 49 .
These and other biologic differences may be due to differen-
[ ]tial interaction of tumor cells with organ-specific factors 50 .
The intrasplenic injection of human pancreatic carcinoma
cells into nude mice produced experimental metastases in
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[ ]the liver and in the lung 51,52 . Cells injected into the
[ ]spleen reach the liver parenchyma within minutes 11 .
Thus, the intrasplenic implantation of cells measures their
ability to grow in the liver parenchyma but fails to measure
cell detachment from the primary pancreatic tumor followed
[ ]by invasion of host stroma 11,12 . This limitation stimulated
the development of an orthotopic model for human pancre-
atic cancer that used tumor fragments, sutured onto the
[ ]pancreas of nude mice 22,51,52 . The use of tumor frag-
[ ]ments avoids the issue of neoplastic heterogeneity 53 and,
thus, the orthotopic inoculation of human pancreatic cancer
cell suspensions is mandatory for reproducible studies of
the biology of pancreatic cancer metastasis. In this study,
we undertook a series of intrapancreatic and intrasplenic
implantation experiments with cell suspensions of a human
pancreatic cancer cell line to select and isolate cell lines
with higher tumorigenicity and increased metastatic poten-
tial. Intrasplenic and intrapancreatic implantation demon-
strated a significant increase in the incidence of primary
( )tumors pancreas, spleen and liver metastasis, as well as
in median number of liver metastases for L3.6sl and L3.6pl
cells over FG cells. Moreover, the incidence and median
number of liver metastases were higher after either intra-
pancreatic or intrasplenic injection of L3.6pl as compared
with L3.6sl cells, suggesting that the repeated pancreas-
to-liver selection procedure isolated cells with higher poten-
[ ]tial for metastasis. More than a century ago, Paget 54
proposed that the outcome of metastasis depended on the
interaction of specific tumor cells with a favorable organ
environment. The present data support the ‘seed and soil’
[ ]hypothesis 54 . After IV injection of the more heteroge-
neous FG cells, a significantly greater differential favoring
lung over liver metastases was produced than after the IV
injection of pancreatic cancer cells selected for their ability
to produce liver metastases.
The increased metastatic potential of the L3.6pl and
L3.6sl variants correlated with expression of several metas-
[ ]tasis-regulating genes 55 . First, E-cadherin is a cell sur-
face glycoprotein involved in calcium-dependent homotypic
[ ]cell-to-cell adhesion 56 . E-cadherin is localized at the
epithelial junction complex and is responsible for the organi-
zation, maintenance, and morphogenesis of epithelial tis-
[ ]sues 57–60 . Reduced levels of E-cadherin are associated
with a decrease in cellular/ tissue differentiation and in-
[ ]creased grade in different epithelial neoplasms 61–65 , and
transfection of E-cadherin–encoding cDNA into invasive
cancer cells has been shown to inhibit motility and invasion
[ ]66 .
Invasion of the host stroma and degradation of the blood
vessel basement membrane are necessary for metastasis
[ ]41–46,67 . The levels of collagenase type IV in human and
rodent neoplasms directly correlate with invasion and
metastasis, and specific inhibitors of matrix metallopro-
teinases have been shown to inhibit tumor cell invasion
[ ] (41–45 . We analyzed the tumors produced by FG cells low
)metastatic by ISH, IHC, and zymography of tumor tissue
lysates and medium conditioned by the respective cultures.
The metastatic variants expressed higher levels of MMP-9
as compared with the low metastatic FG cells. In contrast,
the E-cadherin expression was significantly higher in the FG
tumors than in the metastatic tumors. Thus, a decrease in
the expression of E-cadherin and an increase in collage-
nase type IV activity was associated with enhanced tumor
[ ]invasion and metastasis 37,67–69 .
Increased motility is conducive to tumor cell invasion and
[ ]metastasis 70,71 . Invasive pancreatic cancer cells can
[ ]produce a dissociation factor that increases cell motility 72 .
Similar to our previous study with metastatic human prostate
[ ]cancer 19 , we determined the relative motility of the FG,
L3.6sl, and L3.6pl cells by using a modified Boyden cham-
ber coated with fibronectin. This assay revealed that motility
in vitro directly correlated with production of metastasis.
The progressive growth and metastasis of neoplasms is
dependent on angiogenesis, the extent of which is deter-
mined by the balance between proangiogenic and antian-
giogenic molecules secreted by both tumor and host cells
[ ]73–75 . Among the major molecules identified is bFGF,
which induces the proliferation, migration, proteolytic activ-
[ ]ity, and differentiation of endothelial cells 73,76,77 . VEGF/
VPF induces the proliferation of endothelial cells, increases
the cells’ vascular permeability, and induces the production
[ ]of plasminogen activator by these cells 78–81 . IL-8, a
chemoattractant cytokine produced by a variety of tissues
and blood cells, attracts and activates neutrophils in inflam-
[ ]matory regions and is angiogenic 82,83 . The levels of
MMP-2 and MMP-9 have been associated with active neo-
vascularization because these MMPs can degrade the ECM,
[ ]an essential step in the process of angiogenesis 84 .
The expression of angiogenic molecules differed signifi-
cantly among the 3 pancreatic cell lines. Both in vitro
cultured cells and in vivo tumors derived from L3.6pl and
L3.6sl cells expressed higher levels of VEGF/VPF, bFGF,
IL-8, and MMP-9 than did the low metastatic FG cells or
tumors. The increased expression level of the angiogenic
molecules directly correlated with MVD of the tumor lesions
as measured by immunostaining of endothelial cells with
antibodies against CD31/PECAM-1. Finally, the biological
activity of the angiogenic molecules was proven by their
ability to stimulate growth of HUVEC. In good agreement
with the IHC data, the conditioned media of all 3 pancreatic
tumor cell variants stimulated the growth of HUVECs; how-
ever, the conditioned media of L3.6sl and L3.6pl cells stimu-
lated the growth of HUVECs significantly more than the
conditioned medium of FG cells.
Increased levels of the epidermal growth factor receptor
and its ligand, transforming growth factor, have been asso-
ciated with increased malignancy of human bladder, breast,
[ ]and colon cancers 85–88 . The expression level for these
genes, however, did not vary among the pancreatic cell
lines. The c-met oncogene, which encodes the receptor for
hepatocyte growth factor, has been shown to promote cell
[ ]motility and invasiveness 89–92 . We did not find dis-
cernible differences in expression of c-met among the three
lines.
In summary, we report the development of a reproducible
orthotopic model to study the biology of human pancreatic
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cancer metastasis. We also succeeded in isolating variant
lines with enhanced metastatic properties as demonstrated
by a battery of assays. The availability of these unique cells
and the in vivo model should facilitate in-depth studies to
understand the interaction of metastatic pancreatic cancer
cells with host factors and the design of biologically based
new therapies.
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